The board of Neola Medical, in close dialogue with the main shareholders, has decided to initiate the process of listing the company on Nasdaq First North Growth Market Stockholm, aiming for a listing in the fall of 2020. Over the past year, the company has achieved significant milestones in the development of its lung monitoring product.
Neola Medical has now evolved into an independent company with strong potential in the global lung monitoring market. The listing is an important step in seizing future opportunities for growth and value creation, says Chairman Märta Lewander Xu.
“I am pleased that the shareholders are giving us this opportunity. We have a unique patented technology that enables the direct detection of lung complications, which can be crucial in saving lives. Our first product is aimed at neonatal care, where a large portion of preterm born infants suffer from respiratory difficulties. I see the potential to establish ourselves as a global player in intensive care equipment for patients with respiratory issues,” says CEO Hanna Sjöström.
Eminova Partners AB has been appointed as financial advisor in connection with the process of listing on Nasdaq First North Growth Market Stockholm.
For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com